Skip to main
TNGX

Tango Therapeutics (TNGX) Stock Forecast & Price Target

Tango Therapeutics (TNGX) Analyst Ratings

Based on 11 analyst ratings
Buy
Strong Buy 55%
Buy 36%
Hold 9%
Sell 0%
Strong Sell 0%

Bulls say

Tango Therapeutics is well-positioned in the rapidly growing field of precision oncology and has a strong pipeline of precision therapies, including a promising candidate for non-CNS cancers such as pancreatic and lung cancer, as well as a next-generation brain-penetrant PRMT5 inhibitor for CNS cancers. The company's recent financial results and updated development assumptions for its lead asset, vopimetostat, support a discounted cash flow-based valuation of $11.6B, with a 12-month price objective of $68 per share. Upcoming catalysts, including data presentations and ongoing clinical trials, provide further potential for company growth. Risks to achieving the price target include negative clinical results, delays in pipeline progress, and potential competitive pressures.

Bears say

Tango Therapeutics is heavily focused on discovering and developing precision oncology therapies, specifically targeting KRAS and PRMT5. However, the market is highly competitive, with multiple players already in the market or poised to enter. Additionally, its success hinges on the success of its combination therapies with Revolution Medicines' daraxonrasib and zoldonrasib. If these combinations do not demonstrate efficacy or encounter safety issues, it could result in downside risk to the stock and its price target. There is also the potential for delays in FDA approval for vopimetostat, and any delays or issues could also negatively impact the stock.

Tango Therapeutics (TNGX) has been analyzed by 11 analysts, with a consensus rating of Buy. 55% of analysts recommend a Strong Buy, 36% recommend Buy, 9% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Tango Therapeutics and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Tango Therapeutics (TNGX) Forecast

Analysts have given Tango Therapeutics (TNGX) a Buy based on their latest research and market trends.

According to 11 analysts, Tango Therapeutics (TNGX) has a Buy consensus rating as of Sep 28, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $43.18, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $43.18, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Tango Therapeutics (TNGX)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.